Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer
Purpose The neurokinin-1 receptor antagonist, casopitant, is a weak-to-moderate inhibitor of cytochrome P450 isoenzyme 3A4 (CYP3A) and has the potential to inhibit the metabolism of CYP3A substrates such as docetaxel. Methods Fourteen cancer patients were enrolled in this phase 1, open-label, random...
Gespeichert in:
| Veröffentlicht in: | Cancer chemotherapy and pharmacology 2011-04, Vol.67 (4), p.783-790 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 790 |
|---|---|
| container_issue | 4 |
| container_start_page | 783 |
| container_title | Cancer chemotherapy and pharmacology |
| container_volume | 67 |
| creator | Dandamudi, Uday B. Adams, Laurel M. Johnson, Brendan Bauman, John Morris, Shannon Murray, Sharon Webb, R. Timothy Gartner, Elaina Hohl, Raymond Lewis, Lionel D. |
| description | Purpose
The neurokinin-1 receptor antagonist, casopitant, is a weak-to-moderate inhibitor of cytochrome P450 isoenzyme 3A4 (CYP3A) and has the potential to inhibit the metabolism of CYP3A substrates such as docetaxel.
Methods
Fourteen cancer patients were enrolled in this phase 1, open-label, randomized, two-period crossover study. Intravenous (i.v.) docetaxel was coadministered with oral ondansetron and dexamethasone with (Regimen B) or without (Regimen A) 150 mg single-dose oral casopitant.
Results
The geometric least-squares mean Regimen B: Regimen A ratios (90% confidence interval) for docetaxel maximum plasma concentration and area under the concentration–time curve from time 0 extrapolated to infinity were 0.97 (0.83, 1.12) and 1.06 (0.94, 1.19), respectively. Coadministration of casopitant and docetaxel was well tolerated, with adverse event profiles and absolute neutrophil count nadirs similar for both treatments.
Conclusions
C
max
and AUC of docetaxel were similar when given as monotherapy or when given in combination with casopitant. Likewise, absolute neutrophil count nadirs were similar for docetaxel alone or docetaxel with casopitant. |
| doi_str_mv | 10.1007/s00280-010-1381-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_859058924</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2303009811</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-49cc2609ab12a019b01756417c29eb4e4f9833e1e4297431604e73338878d58d3</originalsourceid><addsrcrecordid>eNp1kE1LxDAQhoMoun78AC9SBPFUnUnSNj2K-AULXvTgqWSzUzfaTWuSRf33ZtlVQfA0M-SZN8PD2CHCGQJU5wGAK8gBIUehMOcbbIRS8ByUFJtsBELKvKhA7rDdEF4AQKIQ22yHQ1GUJYoRexpr85r1bUZtSyYuO6NDP9ioXZpcFmeUDTPt59r0r9ZRtCYsqWlvKOoP6jLrskFHSy6G7N3GWQpwhvw-22p1F-hgXffY4_XVw-VtPr6_ubu8GOdGAsRc1sbwEmo9Qa4B6wlgVZQSK8NrmkiSba2EICTJ60oKLEFSJYRQqlLTQk3FHjtd5Q6-f1tQiM3cBkNdpx31i9CoooZC1Vwm8vgP-dIvvEvHJUglTclagnAFGd-H4KltBm_n2n82CM3SerOy3sByTtYbnnaO1sGLyZymPxvfmhNwsgZ0MLprfTJkwy8nocSSQ-L4igvpyT2T_73w_9-_AEGal0c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>858704843</pqid></control><display><type>article</type><title>Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Dandamudi, Uday B. ; Adams, Laurel M. ; Johnson, Brendan ; Bauman, John ; Morris, Shannon ; Murray, Sharon ; Webb, R. Timothy ; Gartner, Elaina ; Hohl, Raymond ; Lewis, Lionel D.</creator><creatorcontrib>Dandamudi, Uday B. ; Adams, Laurel M. ; Johnson, Brendan ; Bauman, John ; Morris, Shannon ; Murray, Sharon ; Webb, R. Timothy ; Gartner, Elaina ; Hohl, Raymond ; Lewis, Lionel D.</creatorcontrib><description>Purpose
The neurokinin-1 receptor antagonist, casopitant, is a weak-to-moderate inhibitor of cytochrome P450 isoenzyme 3A4 (CYP3A) and has the potential to inhibit the metabolism of CYP3A substrates such as docetaxel.
Methods
Fourteen cancer patients were enrolled in this phase 1, open-label, randomized, two-period crossover study. Intravenous (i.v.) docetaxel was coadministered with oral ondansetron and dexamethasone with (Regimen B) or without (Regimen A) 150 mg single-dose oral casopitant.
Results
The geometric least-squares mean Regimen B: Regimen A ratios (90% confidence interval) for docetaxel maximum plasma concentration and area under the concentration–time curve from time 0 extrapolated to infinity were 0.97 (0.83, 1.12) and 1.06 (0.94, 1.19), respectively. Coadministration of casopitant and docetaxel was well tolerated, with adverse event profiles and absolute neutrophil count nadirs similar for both treatments.
Conclusions
C
max
and AUC of docetaxel were similar when given as monotherapy or when given in combination with casopitant. Likewise, absolute neutrophil count nadirs were similar for docetaxel alone or docetaxel with casopitant.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/s00280-010-1381-2</identifier><identifier>PMID: 20556613</identifier><identifier>CODEN: CCPHDZ</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Aged ; Aged, 80 and over ; Antiemetics - adverse effects ; Antiemetics - pharmacology ; Antineoplastic agents ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - pharmacokinetics ; Antineoplastic Agents - therapeutic use ; Area Under Curve ; Biological and medical sciences ; Cancer Research ; Cross-Over Studies ; Cytochrome P-450 CYP3A ; Cytochrome P-450 CYP3A Inhibitors ; Dexamethasone - pharmacology ; Docetaxel ; Drug Therapy, Combination ; Enzyme Inhibitors - pharmacology ; Female ; Humans ; Least-Squares Analysis ; Leukocyte Count ; Male ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasms - drug therapy ; Neurokinin-1 Receptor Antagonists ; Neutrophils - metabolism ; Oncology ; Ondansetron - pharmacology ; Original Article ; Pharmacology. Drug treatments ; Pharmacology/Toxicology ; Piperazines - adverse effects ; Piperazines - pharmacology ; Piperidines - adverse effects ; Piperidines - pharmacology ; Taxoids - adverse effects ; Taxoids - pharmacokinetics ; Taxoids - therapeutic use</subject><ispartof>Cancer chemotherapy and pharmacology, 2011-04, Vol.67 (4), p.783-790</ispartof><rights>Springer-Verlag 2010</rights><rights>2015 INIST-CNRS</rights><rights>Springer-Verlag 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-49cc2609ab12a019b01756417c29eb4e4f9833e1e4297431604e73338878d58d3</citedby><cites>FETCH-LOGICAL-c400t-49cc2609ab12a019b01756417c29eb4e4f9833e1e4297431604e73338878d58d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00280-010-1381-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00280-010-1381-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24061620$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20556613$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dandamudi, Uday B.</creatorcontrib><creatorcontrib>Adams, Laurel M.</creatorcontrib><creatorcontrib>Johnson, Brendan</creatorcontrib><creatorcontrib>Bauman, John</creatorcontrib><creatorcontrib>Morris, Shannon</creatorcontrib><creatorcontrib>Murray, Sharon</creatorcontrib><creatorcontrib>Webb, R. Timothy</creatorcontrib><creatorcontrib>Gartner, Elaina</creatorcontrib><creatorcontrib>Hohl, Raymond</creatorcontrib><creatorcontrib>Lewis, Lionel D.</creatorcontrib><title>Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><addtitle>Cancer Chemother Pharmacol</addtitle><description>Purpose
The neurokinin-1 receptor antagonist, casopitant, is a weak-to-moderate inhibitor of cytochrome P450 isoenzyme 3A4 (CYP3A) and has the potential to inhibit the metabolism of CYP3A substrates such as docetaxel.
Methods
Fourteen cancer patients were enrolled in this phase 1, open-label, randomized, two-period crossover study. Intravenous (i.v.) docetaxel was coadministered with oral ondansetron and dexamethasone with (Regimen B) or without (Regimen A) 150 mg single-dose oral casopitant.
Results
The geometric least-squares mean Regimen B: Regimen A ratios (90% confidence interval) for docetaxel maximum plasma concentration and area under the concentration–time curve from time 0 extrapolated to infinity were 0.97 (0.83, 1.12) and 1.06 (0.94, 1.19), respectively. Coadministration of casopitant and docetaxel was well tolerated, with adverse event profiles and absolute neutrophil count nadirs similar for both treatments.
Conclusions
C
max
and AUC of docetaxel were similar when given as monotherapy or when given in combination with casopitant. Likewise, absolute neutrophil count nadirs were similar for docetaxel alone or docetaxel with casopitant.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antiemetics - adverse effects</subject><subject>Antiemetics - pharmacology</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - pharmacokinetics</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Area Under Curve</subject><subject>Biological and medical sciences</subject><subject>Cancer Research</subject><subject>Cross-Over Studies</subject><subject>Cytochrome P-450 CYP3A</subject><subject>Cytochrome P-450 CYP3A Inhibitors</subject><subject>Dexamethasone - pharmacology</subject><subject>Docetaxel</subject><subject>Drug Therapy, Combination</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Female</subject><subject>Humans</subject><subject>Least-Squares Analysis</subject><subject>Leukocyte Count</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasms - drug therapy</subject><subject>Neurokinin-1 Receptor Antagonists</subject><subject>Neutrophils - metabolism</subject><subject>Oncology</subject><subject>Ondansetron - pharmacology</subject><subject>Original Article</subject><subject>Pharmacology. Drug treatments</subject><subject>Pharmacology/Toxicology</subject><subject>Piperazines - adverse effects</subject><subject>Piperazines - pharmacology</subject><subject>Piperidines - adverse effects</subject><subject>Piperidines - pharmacology</subject><subject>Taxoids - adverse effects</subject><subject>Taxoids - pharmacokinetics</subject><subject>Taxoids - therapeutic use</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kE1LxDAQhoMoun78AC9SBPFUnUnSNj2K-AULXvTgqWSzUzfaTWuSRf33ZtlVQfA0M-SZN8PD2CHCGQJU5wGAK8gBIUehMOcbbIRS8ByUFJtsBELKvKhA7rDdEF4AQKIQ22yHQ1GUJYoRexpr85r1bUZtSyYuO6NDP9ioXZpcFmeUDTPt59r0r9ZRtCYsqWlvKOoP6jLrskFHSy6G7N3GWQpwhvw-22p1F-hgXffY4_XVw-VtPr6_ubu8GOdGAsRc1sbwEmo9Qa4B6wlgVZQSK8NrmkiSba2EICTJ60oKLEFSJYRQqlLTQk3FHjtd5Q6-f1tQiM3cBkNdpx31i9CoooZC1Vwm8vgP-dIvvEvHJUglTclagnAFGd-H4KltBm_n2n82CM3SerOy3sByTtYbnnaO1sGLyZymPxvfmhNwsgZ0MLprfTJkwy8nocSSQ-L4igvpyT2T_73w_9-_AEGal0c</recordid><startdate>20110401</startdate><enddate>20110401</enddate><creator>Dandamudi, Uday B.</creator><creator>Adams, Laurel M.</creator><creator>Johnson, Brendan</creator><creator>Bauman, John</creator><creator>Morris, Shannon</creator><creator>Murray, Sharon</creator><creator>Webb, R. Timothy</creator><creator>Gartner, Elaina</creator><creator>Hohl, Raymond</creator><creator>Lewis, Lionel D.</creator><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20110401</creationdate><title>Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer</title><author>Dandamudi, Uday B. ; Adams, Laurel M. ; Johnson, Brendan ; Bauman, John ; Morris, Shannon ; Murray, Sharon ; Webb, R. Timothy ; Gartner, Elaina ; Hohl, Raymond ; Lewis, Lionel D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-49cc2609ab12a019b01756417c29eb4e4f9833e1e4297431604e73338878d58d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antiemetics - adverse effects</topic><topic>Antiemetics - pharmacology</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - pharmacokinetics</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Area Under Curve</topic><topic>Biological and medical sciences</topic><topic>Cancer Research</topic><topic>Cross-Over Studies</topic><topic>Cytochrome P-450 CYP3A</topic><topic>Cytochrome P-450 CYP3A Inhibitors</topic><topic>Dexamethasone - pharmacology</topic><topic>Docetaxel</topic><topic>Drug Therapy, Combination</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Female</topic><topic>Humans</topic><topic>Least-Squares Analysis</topic><topic>Leukocyte Count</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasms - drug therapy</topic><topic>Neurokinin-1 Receptor Antagonists</topic><topic>Neutrophils - metabolism</topic><topic>Oncology</topic><topic>Ondansetron - pharmacology</topic><topic>Original Article</topic><topic>Pharmacology. Drug treatments</topic><topic>Pharmacology/Toxicology</topic><topic>Piperazines - adverse effects</topic><topic>Piperazines - pharmacology</topic><topic>Piperidines - adverse effects</topic><topic>Piperidines - pharmacology</topic><topic>Taxoids - adverse effects</topic><topic>Taxoids - pharmacokinetics</topic><topic>Taxoids - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dandamudi, Uday B.</creatorcontrib><creatorcontrib>Adams, Laurel M.</creatorcontrib><creatorcontrib>Johnson, Brendan</creatorcontrib><creatorcontrib>Bauman, John</creatorcontrib><creatorcontrib>Morris, Shannon</creatorcontrib><creatorcontrib>Murray, Sharon</creatorcontrib><creatorcontrib>Webb, R. Timothy</creatorcontrib><creatorcontrib>Gartner, Elaina</creatorcontrib><creatorcontrib>Hohl, Raymond</creatorcontrib><creatorcontrib>Lewis, Lionel D.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dandamudi, Uday B.</au><au>Adams, Laurel M.</au><au>Johnson, Brendan</au><au>Bauman, John</au><au>Morris, Shannon</au><au>Murray, Sharon</au><au>Webb, R. Timothy</au><au>Gartner, Elaina</au><au>Hohl, Raymond</au><au>Lewis, Lionel D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><stitle>Cancer Chemother Pharmacol</stitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>2011-04-01</date><risdate>2011</risdate><volume>67</volume><issue>4</issue><spage>783</spage><epage>790</epage><pages>783-790</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><coden>CCPHDZ</coden><abstract>Purpose
The neurokinin-1 receptor antagonist, casopitant, is a weak-to-moderate inhibitor of cytochrome P450 isoenzyme 3A4 (CYP3A) and has the potential to inhibit the metabolism of CYP3A substrates such as docetaxel.
Methods
Fourteen cancer patients were enrolled in this phase 1, open-label, randomized, two-period crossover study. Intravenous (i.v.) docetaxel was coadministered with oral ondansetron and dexamethasone with (Regimen B) or without (Regimen A) 150 mg single-dose oral casopitant.
Results
The geometric least-squares mean Regimen B: Regimen A ratios (90% confidence interval) for docetaxel maximum plasma concentration and area under the concentration–time curve from time 0 extrapolated to infinity were 0.97 (0.83, 1.12) and 1.06 (0.94, 1.19), respectively. Coadministration of casopitant and docetaxel was well tolerated, with adverse event profiles and absolute neutrophil count nadirs similar for both treatments.
Conclusions
C
max
and AUC of docetaxel were similar when given as monotherapy or when given in combination with casopitant. Likewise, absolute neutrophil count nadirs were similar for docetaxel alone or docetaxel with casopitant.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>20556613</pmid><doi>10.1007/s00280-010-1381-2</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0344-5704 |
| ispartof | Cancer chemotherapy and pharmacology, 2011-04, Vol.67 (4), p.783-790 |
| issn | 0344-5704 1432-0843 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_859058924 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Aged Aged, 80 and over Antiemetics - adverse effects Antiemetics - pharmacology Antineoplastic agents Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use Area Under Curve Biological and medical sciences Cancer Research Cross-Over Studies Cytochrome P-450 CYP3A Cytochrome P-450 CYP3A Inhibitors Dexamethasone - pharmacology Docetaxel Drug Therapy, Combination Enzyme Inhibitors - pharmacology Female Humans Least-Squares Analysis Leukocyte Count Male Medical sciences Medicine Medicine & Public Health Middle Aged Neoplasms - drug therapy Neurokinin-1 Receptor Antagonists Neutrophils - metabolism Oncology Ondansetron - pharmacology Original Article Pharmacology. Drug treatments Pharmacology/Toxicology Piperazines - adverse effects Piperazines - pharmacology Piperidines - adverse effects Piperidines - pharmacology Taxoids - adverse effects Taxoids - pharmacokinetics Taxoids - therapeutic use |
| title | Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T22%3A30%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lack%20of%20effect%20of%20casopitant%20on%20the%20pharmacokinetics%20of%20docetaxel%20in%20patients%20with%20cancer&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=Dandamudi,%20Uday%20B.&rft.date=2011-04-01&rft.volume=67&rft.issue=4&rft.spage=783&rft.epage=790&rft.pages=783-790&rft.issn=0344-5704&rft.eissn=1432-0843&rft.coden=CCPHDZ&rft_id=info:doi/10.1007/s00280-010-1381-2&rft_dat=%3Cproquest_cross%3E2303009811%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=858704843&rft_id=info:pmid/20556613&rfr_iscdi=true |